Labcorp director acquires 897 shares via RSUs

Labcorp Holdings Inc. director Richelle P. Parham acquired 897 shares of common stock on February 11, 2026 through the exercise and conversion of restricted stock units (RSUs) at $0 per share.

Rhea-AI Filing Summary

Labcorp Holdings Inc. director Richelle P. Parham acquired 897 shares of common stock on February 11, 2026 through the exercise and conversion of restricted stock units (RSUs) at $0 per share. This reflects equity compensation vesting rather than an open‑market purchase.

Following the transaction, Parham directly owns 3,366 shares of Labcorp common stock and holds 773 restricted stock units, each representing the contingent right to receive one share of common stock when they vest.

Insider Trade Summary

897 shares exercised/converted

Exercise 2 txns

Insider Parham Richelle P

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	897	$0.00	$0.00
Exercise	Common Stock	897	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 773 contracts (Direct); Common Stock — 3,366 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
2. F2. The Restricted Stock Units vested fully on February 11, 2026.
3. F3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Labcorp (LH) director Richelle P. Parham report?

Richelle P. Parham reported acquiring 897 Labcorp common shares through the exercise and conversion of restricted stock units on February 11, 2026. The Form 4 shows this as equity compensation vesting at a price of $0 per share, not an open‑market stock purchase.

How many Labcorp (LH) shares does Richelle P. Parham own after this Form 4?

After the reported transaction, Richelle P. Parham directly owns 3,366 Labcorp common shares. In addition, she holds 773 restricted stock units, which each represent the contingent right to receive one Labcorp common share upon future vesting.

What was the size and nature of the Labcorp (LH) RSU transaction?

The Form 4 shows 897 restricted stock units converted into 897 Labcorp common shares on February 11, 2026. The transaction code was M, indicating an exercise or conversion of a derivative security, at a reported price of $0 per share as compensation.

Were the Labcorp (LH) shares in this Form 4 bought on the open market?

No, the 897 Labcorp shares were acquired via RSU conversion, not purchased in the open market. The filing classifies the move as an exercise or conversion of restricted stock units granted as equity compensation, with a transaction price of $0 per share.

What do the remaining restricted stock units mean for Labcorp (LH) director Parham?

The filing states that 773 restricted stock units remain outstanding after this transaction. Each unit represents the contingent right to receive one Labcorp common share when it vests, providing additional future equity-based exposure for the director.

When did the reported Labcorp (LH) restricted stock units vest?

According to the disclosure, the restricted stock units vested fully on February 11, 2026. On that date, 897 units converted into 897 Labcorp common shares, reflecting the completion of the vesting schedule for that specific RSU grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 12:56 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parham Richelle P

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		M		897	A	(1)	3,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/11/2026		M			897	(2)	(2)	Common Stock	897	$0	773(3)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. The Restricted Stock Units vested fully on February 11, 2026.

3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Richelle P. Parham	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.